HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $10

Benzinga · 3d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $15 to $10.